. .. Résultats,

. .. Discussion,

. .. Conclusion,

A. Torres, International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilatorassociated pneumonia (VAP) of the, European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT)

, Eur. Respir. J, vol.50, 2017.

M. Woodhead, Guidelines for the management of adult lower respiratory tract infections--full version, Clin. Microbiol. Infect, vol.17, issue.6, pp.1-59, 2011.

W. S. Lim, BTS guidelines for the management of community acquired pneumonia in adults: update, Thorax, vol.64, pp.1-55, 2009.

T. Welte, A. Torres, and D. Nathwani, Clinical and economic burden of communityacquired pneumonia among adults in Europe, Thorax, vol.67, pp.71-79, 2012.

V. Gant and S. Parton, Community-acquired pneumonia, Curr Opin Pulm Med, vol.6, pp.226-233, 2000.

. Bpco, Available at: /maladies-ettraumatismes/maladies-et-infections-respiratoires/bpco-et-insuffisance-respiratoirechronique, p.18, 2019.

M. A. Woodhead, J. T. Macfarlane, J. S. Mccracken, D. H. Rose, and R. G. Finch, Prospective study of the aetiology and outcome of pneumonia in the community, Lancet, vol.1, pp.671-674, 1987.

J. F. Guest and A. Morris, Community-acquired pneumonia: the annual cost to the National Health Service in the UK, Eur. Respir. J, vol.10, pp.1530-1534, 1997.

A. Torres, Severe community-acquired pneumonia. Epidemiology and prognostic factors, Am. Rev. Respir. Dis, vol.144, pp.312-318, 1991.

, ) 12. ERS, ELF. Lung Health in Europe, Les 10 principales causes de mortalité, vol.13, p.22, 2018.

D. Basille, Non-steroidal Anti-inflammatory Drugs may Worsen the Course of Community-Acquired Pneumonia: A Cohort Study, Lung, vol.195, pp.201-208, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01897631

J. D. Chalmers, Risk factors for complicated parapneumonic effusion and empyema on presentation to hospital with community-acquired pneumonia, Thorax, vol.64, pp.592-597, 2009.

M. Kempf, Epidemiology and antimicrobial resistance of Streptococcus pneumoniae in France in 2007: data from the pneumococcus surveillance network, Microb. Drug Resist, vol.17, pp.31-36, 2011.
URL : https://hal.archives-ouvertes.fr/hal-00759836

R. Garraffo and T. Lavrut, Signification clinique des corrélations pharmacocinétique/pharmacodynamie des antibiotiques chez les patients de réanimation, Réanimation, vol.14, pp.264-275, 2005.

J. A. Roberts and J. Lipman, Pharmacokinetic issues for antibiotics in the critically ill patient, Crit. Care Med, vol.37, p.859, 2009.

J. J. De-waele, Risk factors for target non-attainment during empirical treatment with ?-lactam antibiotics in critically ill patients, Intensive Care Med, vol.40, pp.1340-1351, 2014.

J. A. Roberts, C. M. Kirkpatrick, M. S. Roberts, A. J. Dalley, and J. Lipman, Firstdose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis, Int. J. Antimicrob. Agents, vol.35, pp.156-163, 2010.

C. Padoin, Role of therapeutic drug monitoring in pulmonary infections, Rev Mal Respir, vol.34, pp.693-705, 2017.

J. Jamal, M. Abdul-aziz, J. Lipman, and J. A. Roberts, Defining Antibiotic Dosing in Lung Infections, Clinical Pulmonary Medicine, vol.20, p.121, 2013.

D. Honeybourne and D. R. Baldwin, The site concentrations of antimicrobial agents in the lung, J. Antimicrob. Chemother, vol.30, pp.249-260, 1992.

S. Kiem and J. J. Schentag, Interpretation of antibiotic concentration ratios measured in epithelial lining fluid, Antimicrob. Agents Chemother, vol.52, pp.24-36, 2008.

K. A. Rodvold, J. M. George, and L. Yoo, Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents, Clin Pharmacokinet, vol.50, pp.637-664, 2011.

D. Honeybourne, Antibiotic penetration into lung tissues, Thorax, vol.49, pp.104-106, 1994.

R. Wise, A. P. Gillett, B. Cadge, S. R. Durham, and S. Baker, The influence of protein binding upon tissue fluid levels of six beta-lactam antibiotics, J. Infect. Dis, vol.142, pp.77-82, 1980.

M. Cazzola, F. Blasi, C. Terzano, M. G. Matera, and S. A. Marsico, Delivering Antibacterials to the Lungs, Am J Respir Med, vol.1, pp.261-272, 2002.

D. R. Baldwin, D. Honeybourne, and R. Wise, Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance, Antimicrob. Agents Chemother, vol.36, pp.1176-1180, 1992.

J. Dhanani, Antimicrobial chemotherapy and lung microdialysis: a review, Int. J. Antimicrob. Agents, vol.36, pp.491-500, 2010.

J. W. Mouton, Tissue concentrations: do we ever learn?, J. Antimicrob. Chemother, vol.61, pp.235-237, 2008.

S. I. Rennard, Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution, J. Appl. Physiol, vol.60, pp.532-538, 1986.

C. Recommandations and M. Eucast, , 2019.

, Optimisation du traitement par béta-lactamines chez le patient de soins critiques, Données biologiques à l'inclusion, 2018.

. Leucocytes,

, PNN (/mm3

, Lymphocytes (/mm3

A. ,

. Urée,

. Créatinémie,

, Calcul de la clairance selon la formule de Cockroft et Gault (ml/min

, TP

, Plaquettes (/mm3

H. De and L. Maladie, Antibiothérapie : DCI Posologie : Modalités d'administration : ? perfusion continue ? perfusion intermittente si perfusion intermittente : sur quelle durée chaque perfusion ? nb d'administration quotidienne ? ? IVSE ? pompe ? perfusion classique Date de début : _ _/_ _/_ _ à _ _ h_ _ Si perfusion intermittente : date et heure du début de la dernière perfusion : _ _/_ _/_ _ à _ _ h_ _ Si perfusion intermittente

, Nombre de ligne d'antibiotiques : Type d'antibiothérapies antérieures